English
BCMA / Luciferase - CHO Recombinant Cell Line
BCMA / Luciferase - CHO Recombinant Cell Line
Artikelnummer
BPS79724
Verpackungseinheit
2 vials
Hersteller
BPS Bioscience
Verfügbarkeit:
wird geladen...
Preis wird geladen...
Products from BPS Bioscience require a minimum order value above 400€
Applications: Use as BCMA-expressing target cells in co-culture assays with BCMA CAR T-cells to screen for BCMA-specific cell killing
Background: B-Cell Maturation Antigen (BCMA), also known as CD269, is a cell surface receptor of the TNF receptor superfamily that recognizes B-Cell Activating Factor (BAFF). BCMA is preferentially expressed on mature B-lymphocytes and Multiple Myeloma (MM) cells. BCMA is a highly attractive target antigen for immunotherapy not only because of its restricted expression in non-malignant tissue, but also due to its almost universal expression on MM cells. Pre-clinical studies using CAR (Chimeric Antigen Receptor) T-cells targeting BCMA have demonstrated anti-MM activity, and in 2017, the FDA granted BCMA CAR T-Cell immunotherapy the breakthrough designation in treating Multiple Myeloma.
Description: Recombinant CHO-K1 cells constitutively expressing both the human BCMA protein (B-Cell Maturation Antigen or CD269, GenBank accession #NM_001192) and the firefly luciferase reporter. Surface expression of BCMA was confirmed by flow cytometry.
Host Cell Line: CHO
Mycoplasma Testing: This cell line has been screened using the MycoAlert™ Mycoplasma Detection Kit (Lonza,#LT07-118) to confirm the absence of Mycoplasma contamination. MycoAlert Assay Control Set(Lonza, #LT07-518) was used as a positive control.
Storage Stability: Store in liquid nitrogen immediately upon receipt.
Supplied As: Each vial contains ~ 2 x 10^6 cells in 1 ml of 10% DMSO in FBS.
Warnings: Avoid multiple freeze/thaw cycles.
Biosafety Level: BSL-1
Applications: Use as BCMA-expressing target cells in co-culture assays with BCMA CAR T-cells to screen for BCMA-specific cell killing
Background: B-Cell Maturation Antigen (BCMA), also known as CD269, is a cell surface receptor of the TNF receptor superfamily that recognizes B-Cell Activating Factor (BAFF). BCMA is preferentially expressed on mature B-lymphocytes and Multiple Myeloma (MM) cells. BCMA is a highly attractive target antigen for immunotherapy not only because of its restricted expression in non-malignant tissue, but also due to its almost universal expression on MM cells. Pre-clinical studies using CAR (Chimeric Antigen Receptor) T-cells targeting BCMA have demonstrated anti-MM activity, and in 2017, the FDA granted BCMA CAR T-Cell immunotherapy the breakthrough designation in treating Multiple Myeloma.
Description: Recombinant CHO-K1 cells constitutively expressing both the human BCMA protein (B-Cell Maturation Antigen or CD269, GenBank accession #NM_001192) and the firefly luciferase reporter. Surface expression of BCMA was confirmed by flow cytometry.
Host Cell Line: CHO
Mycoplasma Testing: This cell line has been screened using the MycoAlert™ Mycoplasma Detection Kit (Lonza,#LT07-118) to confirm the absence of Mycoplasma contamination. MycoAlert Assay Control Set(Lonza, #LT07-518) was used as a positive control.
Storage Stability: Store in liquid nitrogen immediately upon receipt.
Supplied As: Each vial contains ~ 2 x 10^6 cells in 1 ml of 10% DMSO in FBS.
Warnings: Avoid multiple freeze/thaw cycles.
Biosafety Level: BSL-1
| Artikelnummer | BPS79724 |
|---|---|
| Hersteller | BPS Bioscience |
| Hersteller Artikelnummer | 79724 |
| Verpackungseinheit | 2 vials |
| Mengeneinheit | PAK |
| Wirt | Hamster |
| Produktinformation (PDF) | Download |
| MSDS (PDF) |
|
Verwandte Artikel
Markieren Sie die Artikel, um Sie dem Warenkorb hinzuzufügen oder
Immer für Sie da
Gernot Ensinger, M.Sc.
Laurent Haze
